Rho Subfamily Research Articles

A thirty-year quest for a role of R-Ras in cancer: from an oncogene to a multitasking GTPase

Since the identification of R-Ras, which is the first Ras-related GTPase isolated based on sequence similarity to the classical RAS oncogene, more than 160 members of the Ras superfamily of GTPases have been identified and classified into the Ras, Rho, Rap, Rab, Ran, Arf, Rheb, RGK, Rad, Rit, and Miro subfamilies. R-Ras belongs to the Ras subfamily of small G-proteins, which are frequently implicated in cell growth and differentiation. Although the roles of R-Ras in cellular transformation and integrin-mediated cell adhesion have been extensively studied, the physiological function of this enigmatic G-protein was only revealed when a mouse strain deficient in R-Ras was generated. In parallel, a plethora of research findings also linked R-Ras with processes including tumor angiogenesis, axon guidance, and immune cell trafficking. Several upstream factors that modulate R-Ras GTP-binding were identified including Notch, semaphorin, and chemokine C-C motif ligand 21. A review of our evolving understanding of the role of R-Ras in oncogenesis is timely, as this year marks the 30th anniversary of the publication describing the cloning of R-Ras.

Quantification of small GTPase glucosylation by clostridial glucosylating toxins using multiplexed MRM analysis.

Large clostridial toxins mono-O-glucosylate small GTPases of the Rho and Ras subfamily. As a result of glucosylation, the GTPases are inhibited and thereby corresponding downstream signaling pathways are disturbed. Current methods for quantifying the extent of glucosylation include sequential [14 C]glucosylation, sequential [32 P]ADP-ribosylation, and Western Blot detection of nonglucosylated GTPases, with neither method allowing the quantification of the extent of glucosylation of an individual GTPase. Here, we describe a novel MS-based multiplexed MRM assay to specifically quantify the glucosylation degree of small GTPases. This targeted proteomics approach achieves a high selectivity and reproducibility, which allows determination of the in vivo substrate pattern of glucosylating toxins. As proof of principle, GTPase glucosylation was analyzed in CaCo-2 cells treated with TcdA, and glucosylation kinetics were determined for RhoA/B, RhoC, RhoG, Ral, Rap1, Rap2, (H/K/N)Ras, and R-Ras2.

Two Small Molecules, ZCL278 and AZA197 Show Promise in Influencing Protein Interactions Involving the Ras-Related Protein Cell division cycle 42 [Cdc42] to Modulate Its Oncogenic Potential

Cdc42 is a member of the Rho subfamily of Ras-related proteins, which were among the first oncogenic proteins to be identified as playing a sig-nificant role in a variety of cellular events [Barbacaid, 1987, Ann. Rev. Biochem]. Equally important, Protein-Protein Interactions [PPIs] involving Cdc42 continue to highlight the role of Ras-related proteins’ relevance to cancer. As these proteins have been considered incapable of being “druggable”, due to a perceived lack of binding surface[s] that are amenable to small molecule targeting, there remains limited development of therapies to tackle diseased states caused by Cdc42-stimulated hyperactivity. Thusly, it has become important to characterize molecular details, including dynamics, of PPIs involving Cdc42 that may lend themselves as potential targets for therapeutic approaches. Recently, two small molecules, ZCL278 and AZA197, have shown promise in directly targeting Cdc42 to influence PPIs that are capable of causing Cdc42-stimulated abnormal signaling. In this editorial, we highlight recent studies that show case how these two small molecules may influence Cdc42-protein interactions.

C-terminal domain (CTD) phosphatase links Rho GTPase signaling to Pol II CTD phosphorylation in Arabidopsis and yeast

Rho GTPases, including the Rho, Cdc42, Rac, and ROP subfamilies, act as pivotal signaling switches in various growth and developmental processes. Compared with the well-defined role of cytoskeletal organization in Rho signaling, much less is known regarding transcriptional regulation. In a mutant screen for phenotypic enhancers of transgenic Arabidopsis plants expressing a constitutively active form of ROP2 (designated CA1-1), we identified RNA polymerase II (Pol II) C-terminal domain (CTD) phosphatase-like 1 (CPL1) as a transcriptional regulator of ROP2 signaling. We show that ROP2 activation inhibits CPL1 activity by promoting its degradation, leading to an increase in CTD Ser5 and Ser2 phosphorylation. We also observed similar modulation of CTD phosphorylation by yeast Cdc42 GTPase and enhanced degradation of the yeast CTD phosphatase Fcp1 by activated ROP2 signaling. Taken together, our results suggest that modulation of the Pol II CTD code by Rho GTPase signaling represents an evolutionarily conserved mechanism in both unicellular and multicellular eukaryotes.

Control of developmental networks by Rac/Rho small GTPases: How cytoskeletal changes during embryogenesis are orchestrated.

Small GTPases in the Rho family act as major nodes with functions beyond cytoskeletal rearrangements shaping the Caenorhabditis elegans embryo during development. These small GTPases are key signal transducers that integrate diverse developmental signals to produce a coordinated response in the cell. In C. elegans, the best studied members of these highly conserved Rho family small GTPases, RHO‐1/RhoA, CED‐10/Rac, and CDC‐42, are crucial in several cellular processes dealing with cytoskeletal reorganization. In this review, we update the functions described for the Rho family small GTPases in spindle orientation and cell division, engulfment, and cellular movements during C. elegans embryogenesis, focusing on the Rho subfamily Rac.Please also see the video abstract here

Therapeutic effects of the Rho GTPase modulator CNF1 in a model of Parkinson’s disease

Recent evidence suggests an early involvement of dopaminergic (DA) processes and terminals in Parkinson’s disease (PD). The arborization of neurons depends on the actin cytoskeleton, which in turn is regulated by small GTPases of the Rho family, encompassing Rho, Rac and Cdc42 subfamilies. Indeed, some reports point to a role for Rac and Cdc42 signaling in the pathophysiology of inherited parkinsonisms. We thus investigated the potential therapeutic effect of the modulation of cerebral Rho GTPases in PD. Cytotoxic necrotizing factor 1 (CNF1), a 114 kDa protein toxin produced by Escherichia coli, permanently activates RhoA, Rac1 and Cdc42 in intact cells. We report that the modulation of Rho GTPases by CNF1 results in hypertrophy of DA cell processes of cultured substantia nigra neurons, including increase in length, branching and varicosity. In vivo, the treatment corrects long-standing motor and biochemical asymmetries and restores degenerated nigrostriatal DA tissue after 6-hydroxydopamine lesion. We conclude that the pharmacological modulation of Rho GTPases shows neurorestorative potential and represents a promising avenue in the treatment PD. The study also suggests that naturally occurring molecules acting on Rho GTPase signaling, such as some bacterial protein toxins, might play a role in the development of PD.

ROCK activity regulates functional tight junction assembly during blastocyst formation in porcine parthenogenetic embryos.

The Rho-associated coiled-coil-containing protein serine/threonine kinases 1 and 2 (ROCK1 and ROCK2) are Rho subfamily GTPase downstream effectors that regulate cell migration, intercellular adhesion, cell polarity, and cell proliferation by stimulating actin cytoskeleton reorganization. Inhibition of ROCK proteins affects specification of the trophectoderm (TE) and inner cell mass (ICM) lineages, compaction, and blastocyst cavitation. However, the molecules involved in blastocyst formation are not known. Here, we examined developmental competence and levels of adherens/tight junction (AJ/TJ) constituent proteins, such as CXADR, OCLN, TJP1, and CDH1, as well as expression of their respective mRNAs, after treating porcine parthenogenetic four-cell embryos with Y-27632, a specific inhibitor of ROCK, at concentrations of 0, 10, 20, 100 µM for 24 h. Following this treatment, the blastocyst development rates were 39.1, 20.7, 10.0, and 0% respectively. In embryos treated with 20 µM treatment, expression levels of CXADR, OCLN, TJP1, and CDH1 mRNA and protein molecules were significantly reduced (P < 0.05). FITC-dextran uptake assay revealed that the treatment caused an increase in TE TJ permeability. Interestingly, the majority of the four-cell and morula embryos treated with 20 µM Y-27643 for 24 h showed defective compaction and cavitation. Taken together, our results indicate that ROCK activity may differentially affect assembly of AJ/TJs as well as regulate expression of genes encoding junctional proteins.

LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.

BackgroundThe increasing availability of resequencing data has led to a better understanding of the most important genes in cancer development. Nevertheless, the mutational landscape of many tumor types is heterogeneous and encompasses a long tail of potential driver genes that are systematically excluded by currently available methods due to the low frequency of their mutations. We developed LowMACA (Low frequency Mutations Analysis via Consensus Alignment), a method that combines the mutations of various proteins sharing the same functional domains to identify conserved residues that harbor clustered mutations in multiple sequence alignments. LowMACA is designed to visualize and statistically assess potential driver genes through the identification of their mutational hotspots.ResultsWe analyzed the Ras superfamily exploiting the known driver mutations of the trio K-N-HRAS, identifying new putative driver mutations and genes belonging to less known members of the Rho, Rab and Rheb subfamilies. Furthermore, we applied the same concept to a list of known and candidate driver genes, and observed that low confidence genes show similar patterns of mutation compared to high confidence genes of the same protein family.ConclusionsLowMACA is a software for the identification of gain-of-function mutations in putative oncogenic families, increasing the amount of information on functional domains and their possible role in cancer. In this context LowMACA emphasizes the role of genes mutated at low frequency otherwise undetectable by classical single gene analysis.LowMACA is an R package available at http://www.bioconductor.org/packages/release/bioc/html/LowMACA.html. It is also available as a GUI standalone downloadable at: https://cgsb.genomics.iit.it/wiki/projects/LowMACAElectronic supplementary materialThe online version of this article (doi:10.1186/s12859-016-0935-7) contains supplementary material, which is available to authorized users.

Multi-facets of Serum Response Factor in the Cardiac Pathophysiology

Heart is a vital organ that pumps blood to all body parts of an organism through synchronous contraction and relaxation movements of the cardiac muscle. Homeostasis of cardiac muscle is thus necessary for normal heart functioning. Fine tuning of the cardiac muscle is maintained by numerous signal transduction pathways which are not only responsible for physiological functions, but pathological lesions as well. Many intrinsic or extrinsic stimuli like physical stress, pressure overload, hypertension, etc. disturbs cardiac homeostasis and affects signal transduction pathways causing disease phenotype such as hypertrophy, cardiomyopathy, and consequent heart failure. The most unique characteristic of cardiomyocytes is that they are terminally differentiated and do not grow in number postnatally, they only grow in size by lateral/longitudinal hypertrophy. Hypertrophy is also induced in cardiomyocytes to overcome acute wall tension caused by various biochemical stresses. At molecular level, several signalling pathways and interacting networks have been implicated with the heart’s molecular response to physiological and/or pathological biomechanical stress, reviewed in detail elsewhere [1‐4]. Calcineurin, a Ca2+-calmodulin activation dependent serine‐threonine phosphatase is one of the key signaling molecules strongly linked to cardiac hypertrophy [5‐8]. Its prohypertrophic effects are well established through series of in vitro and in vivo studies and is highly correlated with human patients of cardiac hypertrophy and cardiomyopathy [6,9]. Moreover, Calcineurin signaling is found to be interconnected with many other important hypertrophic pathways, such as those controlled by glycogen synthase kinase (GSK) 3β and mitogenactivated protein (MAP) kinase signaling [3,10]. Interestingly, Rho family of small GTPase proteins, consisting of Rho, Rac, and Cdc42 subfamilies regulate the sarcomere organization in cardiomyocytes, one of the hallmarks of hypertrophy [11]. These GTPase effectors are also upstream of a very important cardiac signaling molecule, serum response factor (SRF) [12,13].

Rho GTPase signaling promotes constitutive expression and release of TGF-β2 by human trabecular meshwork cells

Elevated intraocular pressure (IOP) is causally implicated in the pathophysiology of primary open-angle glaucoma (POAG). The molecular mechanisms responsible for elevated IOP remain elusive, but may involve aberrant expression and signaling of transforming growth factor (TGF)-β2 within the trabecular meshwork (TM). Consistent with previously published studies, we show here that exogenous addition of TGF-β2 to cultured porcine anterior segments significantly attenuates outflow facility in a time-dependent manner. By comparison, perfusing segments with a TGFβRI/ALK-5 antagonist (SB-431542) unexpectedly elicited a significant and sustained increase in outflow facility, implicating a role for TM-localized constitutive expression and release of TGF-β2. Consistent with this thesis, cultured primary or transformed (GTM3) quiescent human TM cells were found to constitutively express and secrete measurable amounts of biologically-active TGF-β2. Disrupting monomeric GTPase post-translational prenylation and activation with lovastatin or GGTI-298 markedly reduced constitutive TGF-β2 expression and release. Specifically, inhibiting the Rho subfamily of GTPases with C3 exoenzyme similarly reduced constitutive expression and secretion of TGF-β2. These findings suggest that Rho GTPase signaling, in part, regulates constitutive expression and release of biologically-active TGF-β2 from human TM cells. Localized constitutive expression and release of TGF-β2 by TM cells may promote or exacerbate elevation of IOP in POAG.

Podocyte-specific deletion of Rac1 leads to aggravation of renal injury in STZ-induced diabetic mice

Rac1, a GTPase of the Rho subfamily, has a crucial role in cytoskeletal architecture, as well as the regulation of cell migration and growth. However, renal injury in mice with podocyte-specific deletion of Rac1 has yet to be elucidated fully due to conflicting findings. Herein, we identified a possible role for Rac1 in podocytes of streptozotocin- (STZ) induced diabetic mice. The urinary albumin/creatinine ratio (ACR) in the knockout (KO) group was significantly higher than that in the wild type (WT) group at any week of age. A more marked ACR increase was observed in STZ/KO group than STZ/WT group, although ACR did increase with weeks of age in both diabetic groups. The kidney sections from diabetic mice revealed a glomerular hypertrophy with mesangial expansion, but there was no appreciable difference in glomerular findings under a light microscope between STZ/WT and STZ/KO mice. However, an electron microscopy analysis revealed that regardless of the presence or absence of diabetes, both KO (KO and STZ/KO) groups had a higher rate of foot process effacement compared with both WT (WT and STZ/WT) groups. The expression levels of the slit diaphragm protein, podocin, was reduced with the induction of diabetes, and the levels in the STZ/KO group experienced a further reduction compared with the STZ/WT group. The number of WT1-positive cells in the STZ/KO group was more significantly decreased than that in the other three groups. In contrast, the numbers of cleaved caspase 3- and TUNEL-positive cells in the glomeruli of the STZ/KO group were more increased than those in the STZ/WT group.Thus, this study provides evidence that podocyte-specific deletion of Rac1 results in morphological alteration in podocytes, and that the induction of apoptosis or decreased expression of the slit diaphragm proteins by hyperglycemic stimuli are associated with the progression of diabetic nephropathy.

In vivo hematopoietic Myc activation directs a transcriptional signature in endothelial cells within the bone marrow microenvironment.

Cancer pathogenesis involves tumor-intrinsic genomic aberrations and tumor-cell extrinsic mechanisms such as failure of immunosurveillance and structural and functional changes in the microenvironment. Using Myc as a model oncogene we established a conditional mouse bone marrow transduction/transplantation model where the conditional activation of the oncoprotein Myc expressed in the hematopoietic system could be assessed for influencing the host microenvironment. Constitutive ectopic expression of Myc resulted in rapid onset of a lethal myeloproliferative disorder with a median survival of 21 days. In contrast, brief 4-day Myc activation by means of the estrogen receptor (ER) agonist tamoxifen did not result in gross changes in the percentage/frequency of hematopoietic lineages or hematopoietic stem/ progenitor cell (HSPC) subsets, nor did Myc activation significantly change the composition of the non-hematopoietic microenvironment defined by phenotyping for CD31, ALCAM, and Sca-1 expression. Transcriptome analysis of endothelial CD45- Ter119- cells from tamoxifen-treated MycER bone marrow graft recipients revealed a gene expression signature characterized by specific changes in the Rho subfamily pathway members, in the transcription-translation-machinery and in angiogenesis. In conclusion, intra-hematopoietic Myc activation results in significant transcriptome alterations that can be attributed to oncogene-induced signals from hematopoietic cells towards the microenvironment, e. g. endothelial cells, supporting the idea that even pre-leukemic HSPC highjack components of the niche which then could protect and support the cancer-initiating population.

Using kernelized partial canonical correlation analysis to study directly coupled side chains and allostery in small G proteins.

Motivation: Inferring structural dependencies among a protein’s side chains helps us understand their coupled motions. It is known that coupled fluctuations can reveal pathways of communication used for information propagation in a molecule. Side-chain conformations are commonly represented by multivariate angular variables, but existing partial correlation methods that can be applied to this inference task are not capable of handling multivariate angular data. We propose a novel method to infer direct couplings from this type of data, and show that this method is useful for identifying functional regions and their interactions in allosteric proteins.Results: We developed a novel extension of canonical correlation analysis (CCA), which we call ‘kernelized partial CCA’ (or simply KPCCA), and used it to infer direct couplings between side chains, while disentangling these couplings from indirect ones. Using the conformational information and fluctuations of the inactive structure alone for allosteric proteins in the Ras and other Ras-like families, our method identified allosterically important residues not only as strongly coupled ones but also in densely connected regions of the interaction graph formed by the inferred couplings. Our results were in good agreement with other empirical findings. By studying distinct members of the Ras, Rho and Rab sub-families, we show further that KPCCA was capable of inferring common allosteric characteristics in the small G protein super-family.Availability and implementation: https://github.com/lsgh/ismb15Contact: lsoltang@uwaterloo.ca

RhoGTPases - A novel link between cytoskeleton organization and cisplatin resistance.

For more than three decades, platinum compounds have been the first line treatment for a wide spectrum of solid tumors. Yet, cisplatin resistance is a major impediment in cancer therapy, and deciphering the mechanisms underlying chemoresistance is crucial for the development of novel therapies with enhanced efficacy. The Rho subfamily of small GTPases plays a significant role in cancer progression, and a growing body of evidence points toward the involvement of these proteins in anticancer drug resistance, including cisplatin resistance. The cycling between active and inactive states, governed by the balance between their GEFs, GAPs and GDIs, RhoGTPases, acts as molecular switches with a pivotal role in actin cytoskeleton organization. The Rho subfamily of proteins is involved in many key cellular processes including adhesion, vesicular trafficking, proliferation, survival, cell morphology and cell-matrix interactions. Although RhoA, RhoB and RhoC are highly homologous and share some upstream regulators and downstream effectors, they each have different roles in cancer progression and chemoresistance. While RhoA and RhoC are upregulated in many tumors and can stimulate transformation, RhoB appears to exhibit tumor suppressor characteristics with proapoptotic effects. In the current review, we discuss the role of Rho subfamily of proteins in cancer, and focus on their involvement in intrinsic and acquired drug resistance.

Rac1 modulates cardiomyocyte adhesion during mouse embryonic development

Rac1, a member of the Rho subfamily of small GTPases, is involved in morphogenesis and differentiation of many cell types. Here we define a role of Rac1 in cardiac development by specifically deleting Rac1 in the pre-cardiac mesoderm using the Nkx2.5-Cre transgenic driver line. Rac1-conditional knockout embryos initiate heart development normally until embryonic day 11.5 (E11.5); their cardiac mesoderm is specified, and the heart tube is formed and looped. However, by E12.5-E13.5 the mutant hearts start failing and embryos develop edema and hemorrhage which is probably the cause for the lethality observed soon after. The hearts of Rac1-cKO embryos exhibit disorganized and thin myocardial walls and defects in outflow tract alignment. No significant differences of cardiomyocyte death or proliferation were found between developing control and mutant embryos. To uncover the role of Rac1 in the heart, E11.5 primary heart cells were cultured and analyzed in vitro. Rac1-deficient cardiomyocytes were less spread, round and loosely attached to the substrate and to each other implying that Rac1-mediated signaling is required for appropriate cell–cell and/or cellmatrix adhesion during cardiac development.

Abstract A35: Targeting Ras downstream to control motions: Rho GTPases

Abstract Ras activation is at the center of many signaling cascades that drive cell transformation and carcinogenesis. Strategies targeting inhibition of cellular functions of Ras can be multifaceted, from its upstream elements such as growth factors and integrin receptors to its remote downstream elements. Cell motility is one such major element that controls whether a cancer cell can be lethal to the human body. Without gaining cancer unique motile ability, a cancer cell's deadly impact of metastasis would be crippled and be eliminated through available anti-neoplastic approaches. There has been important progress in the discovery of small molecule modulators targeting the control machinery of cell motions, notably Rho subfamily of small GTPases, which is part of the Ras superfamily proteins. The classical proteins of the Rho GTPases are RhoA, Rac1, and Cdc42, which control the cytoplasmic tension (RhoA), cellular crawling (Rac1), and cellular scouting (Cdc42), respectively. Because these proteins are essential for cancer cell motility, establishment of a toolbox for the molecular modulators of their functions would significantly enhance the development of potential therapeutics aimed at targeting these pathways. Over the past decade, chemical compounds targeting RhoA pathway (Y-27632: Nature, 1997) and Rac1 (NSC23766: PNAS, 2004) became available. Our recent identification of a small molecule modulating Cdc42 (ZCL278: PNAS, 2013) has provided a complete reservoir that could be used to explore their differential effects on cancer cell behavior. ZCL278 and NSC23766 suppressed prostate cancer cell motility and they showed differential effects on cell survival. While ZCL278 did not decrease cell viability, NSC23766 did so in the same time frame. Our recent unpublished studies also found that they differentially influence cell cycle progression. Cells derived from different cancer types responded differently to Rac1 and Cdc42 modulation. Furthermore, cells derived from different individuals of the same cancer types responded differently, emphasizing the heterogeneity of potential drug responses of different cancers or same cancer types from different individuals. For example, in prostate cancer cells, ZCL278 increased S-phase block, resulting a diminished G2/M-phase in a dose-dependent manner whereas the effects of NSC23766 on G2/M reduction were not significant. In lung cancer cells, the effects of ZCL278 and NSC23776 on cell cycle were modified. NSC23766 did not increase apoptosis of some lung cancer cell types at all. Therefore, ZCL278 and NSC23766 can suppress cell motility, cell proliferation and cell survival differently in different cancers. Our studies will provide the first glimpse of the effects of ZCL278 and NSC23766 on 5 different cancer types including breast, colon, lung, pancreas, and prostate cancer. Understanding the mechanisms of the cancer heterogeneity and the incorporation of differentiating biomarkers would significantly increase the intended efficacy of cancer therapeutics targeting Ras and its downstream elements. Our studies are supported in part by NIH grants CA111891, CA165202, and HL085752. Citation Format: Qun Lu, Christi Boykin, Huchen Zhou, Amy Friesland, Yan-Hua Chen. Targeting Ras downstream to control motions: Rho GTPases. [abstract]. In: Proceedings of the AACR Special Conference on RAS Oncogenes: From Biology to Therapy; Feb 24-27, 2014; Lake Buena Vista, FL. Philadelphia (PA): AACR; Mol Cancer Res 2014;12(12 Suppl):Abstract nr A35. doi: 10.1158/1557-3125.RASONC14-A35

Mouse Macrophages Completely Lacking Rho Subfamily GTPases (RhoA, RhoB, and RhoC) Have Severe Lamellipodial Retraction Defects, but Robust Chemotactic Navigation and Altered Motility

RhoA is thought to be essential for coordination of the membrane protrusions and retractions required for immune cell motility and directed migration. Whether the subfamily of Rho (Ras homolog) GTPases (RhoA, RhoB, and RhoC) is actually required for the directed migration of primary cells is difficult to predict. Macrophages isolated from myeloid-restricted RhoA/RhoB (conditional) double knock-out (dKO) mice did not express RhoC and were essentially "pan-Rho"-deficient. Using real-time chemotaxis assays, we found that retraction of the trailing edge was dissociated from the advance of the cell body in dKO cells, which developed extremely elongated tails. Surprisingly, velocity (of the cell body) was increased, whereas chemotactic efficiency was preserved, when compared with WT macrophages. Randomly migrating RhoA/RhoB dKO macrophages exhibited multiple small protrusions and developed large "branches" due to impaired lamellipodial retraction. A mouse model of peritonitis indicated that monocyte/macrophage recruitment was, surprisingly, more rapid in RhoA/RhoB dKO mice than in WT mice. In comparison with dKO cells, the phenotypes of single RhoA- or RhoB-deficient macrophages were mild due to mutual compensation. Furthermore, genetic deletion of RhoB partially reversed the motility defect of macrophages lacking the RhoGAP (Rho GTPase-activating protein) myosin IXb (Myo9b). In conclusion, the Rho subfamily is not required for "front end" functions (motility and chemotaxis), although both RhoA and RhoB are involved in pulling up the "back end" and resorbing lamellipodial membrane protrusions. Macrophages lacking Rho proteins migrate faster in vitro, which, in the case of the peritoneum, translates to more rapid in vivo monocyte/macrophage recruitment.

Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome.

Cytosolic inflammasome complexes mediated by a pattern recognition receptor (PRR) defend against pathogen infection by activating caspase 1. Pyrin, a candidate PRR, can bind to the inflammasome adaptor ASC to form a caspase 1-activating complex. Mutations in the Pyrin-encoding gene, MEFV, cause a human autoinflammatory disease known as familial Mediterranean fever. Despite important roles in immunity and disease, the physiological function of Pyrin remains unknown. Here we show that Pyrin mediates caspase 1 inflammasome activation in response to Rho-glucosylation activity of cytotoxin TcdB, a major virulence factor of Clostridium difficile, which causes most cases of nosocomial diarrhoea. The glucosyltransferase-inactive TcdB mutant loses the inflammasome-stimulating activity. Other Rho-inactivating toxins, including FIC-domain adenylyltransferases (Vibrio parahaemolyticus VopS and Histophilus somni IbpA) and Clostridium botulinum ADP-ribosylating C3 toxin, can also biochemically activate the Pyrin inflammasome in their enzymatic activity-dependent manner. These toxins all target the Rho subfamily and modify a switch-I residue. We further demonstrate that Burkholderia cenocepacia inactivates RHOA by deamidating Asn 41, also in the switch-I region, and thereby triggers Pyrin inflammasome activation, both of which require the bacterial type VI secretion system (T6SS). Loss of the Pyrin inflammasome causes elevated intra-macrophage growth of B. cenocepacia and diminished lung inflammation in mice. Thus, Pyrin functions to sense pathogen modification and inactivation of Rho GTPases, representing a new paradigm in mammalian innate immunity.

PS216. Zizimin1 Overexpression Impairs Vascular Morphogenesis

Objectives: The Rho subfamily of small GTPases, including RhoA, Rac1, and Cdc42, regulates diverse cellular functions, including polarity, migration, and actin-based cytoskeleton dynamics. Our prior studies established an essential role for Cdc42 in vascular network assembly, demonstrating that the genetic inactivation of Cdc42 yields defective vascular morphogenesis due to impaired migration of endothelial precursor cells. We have further shown that protein kinase Ciota and glycogen synthase kinase-3b are downstream effectors of Cdc42 and are involved in mediating vascular network assembly. However, the guanine nucleotide exchange factors (GEFs) that activate Cdc42, remain unknown. Methods: We performed affinity pulldown assays using a nucleotide-free Cdc42 G15A mutant that specifically binds to Cdc42 GEFs. Mass spectrometric analysis identified Zizimin1, an upstream regulatory protein, as a candidate Cdc42 GEF. Results: During vasculogenesis in embryoid bodies (EBs) differentiated from embryonic stem cells, Zizimin1 is highly expressed in aggregated endothelial cell precursors before vascular network formation. Surprisingly, stable overexpression of Zizimin1 in EBs resulted in the inhibition of blood vessel formation compared with control, evidenced by immunohistochemistry demonstrating loss of vascular network development. Affinity pulldown assay helped to elucidate that overexpression of Zizimin1 increases Cdc42 activity; however, the activation of Rac1 and RhoA is significantly inhibited. Conclusions: Because Rac1 and RhoA signaling has been reported to play an essential role in embryonic blood vessel formation, our results suggest that the interplay betweenRhoGTPases guides vascular network assembly during development. Furthermore, these findings provide novel insights into the mechanisms of embryonic vasculogenesis and also important new information for the design of potential proangiogenic and/or antiangiogenic therapies.

Abstract 331: The Role of Zizimin1 Overexpression in Vascular Morphogenesis

Objectives: The Rho subfamily of small GTPases, including RhoA, Rac1, and Cdc42, regulates diverse cellular functions, including polarity and migration. Our prior studies established an essential role for Cdc42 in vascular network assembly, demonstrating that the genetic inactivation of Cdc42 yields defective vascular morphogenesis due to impaired migration of endothelial precursor cells. We have further shown that protein kinase Ciota and glycogen synthase kinase-3 Beta are downstream effectors of Cdc42 involved in mediating vascular network assembly. The objective of this study was to elucidate the guanine nucleotide exchange factors (GEFs) that activate Cdc42; specifically, we investigated the role of Zizimin1 and its effects on Cdc42 and vasculogenesis. Methods: We performed affinity pulldown assays using a nucleotide-free Cdc42 G15A mutant that specifically binds to Cdc42 GEFs. Mass spectrometric analysis identified Zizimin1 as a candidate Cdc42 GEF. Results: During vasculogenesis in embryoid bodies (EBs) differentiated from embryonic stem cells, Zizimin1 is highly expressed in aggregated endothelial cell precursors prior to vascular network assembly, mainly localizing to the Golgi apparatus. Surprisingly, stable overexpression of Zizimin1 in EBs resulted in inhibition of blood vessel formation, as evidenced by immunofluorescence microscopy demonstrating loss of vascular network development. Affinity pulldown assay showed that overexpression of Zizimin1 in fact increases Cdc42 activity; however, the activation of Rac1 and RhoA is significantly inhibited. Further, ectopically expressed Zizimin1 was also detected in the Golgi apparatus, co-localizing with Cdc42. Conclusions: Since Rac1 and RhoA signaling has been reported to play an essential role in blood vessel formation, our results suggest that the interplay between Rho GTPases guides vascular network assembly during development. Furthermore, we speculate that Zizimin1 overexpression, leading to overactivation of Cdc42 in the Golgi apparatus, may hinder cell migration. These findings provide novel insights into the mechanisms of embryonic vasculogenesis and also important new information for the design of potential pro- and/or anti- angiogenic therapies.